<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157894">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01655693</url>
  </required_header>
  <id_info>
    <org_study_id>BA2011/03/04</org_study_id>
    <secondary_id>2011-002843-92</secondary_id>
    <nct_id>NCT01655693</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma</brief_title>
  <acronym>ReLive</acronym>
  <official_title>Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Supportive Care (BSC) in Patients Suffering From Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioAlliance Pharma SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioAlliance Pharma SA</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase III study is to determine whether Doxorubicin Transdrug (DT) is
      effective in the treatment of patients suffering from advanced Hepatocellular Carcinoma
      (HCC) after failure or intolerance to Sorafenib. Patients with HCC with or without cirrhosis
      and with good liver functions are eligible. Only those who can not benefit from treatment
      for which efficacy is demonstrated are eligible.

      These patients are usually proposed either best supportive care (BSC) or participation to
      clinical trials. Patients eligible for the RELIVE study will receive either DT at 20 mg/m2
      or DT at 30 mg/m2 or the BSC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doxorubicin-Transdrug™ (DT) is a nanoparticle formulation of doxorubicin.In in vitro and in
      vivo models, DT was shown to overcome the multidrug resistance (MDR) and to be more
      effective than doxorubicin on both sensitive and resistant tumour models and in particular
      in the X/myc bi-transgenic MDR murine model of HCC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival(OS) in each group</measure>
    <time_frame>at 1 year (expected average)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Survival status will be collected at each visit (at least every 2 weeks) during the study treatment period and then every 3 months until death for an expected average of 1 year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of all Treatment Emergent Adverse Events according to NCI-CTC v4.0 scale in each groups</measure>
    <time_frame>until 2 months after last treatment intake</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events will be collected at each visit (at least every 2 weeks) during the study treatment period, and then 2 months after the last treatment intake for an expected average of 6 months.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Doxorubicin Transdrug (DT) at 20mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin Transdrug (DT) at 30 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Supportive Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized in the control group  will receive treatment according to the investigator's choice, until disease progression or toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>Doxorubicin Transdrug (DT) at 20mg/m2</arm_group_label>
    <other_name>Doxorubicin Transdrug (DT) at 20mg/m2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>Doxorubicin Transdrug (DT) at 30 mg/m2</arm_group_label>
    <other_name>Doxorubicin Transdrug (DT) at 30mg/m2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <arm_group_label>Best Supportive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-breast feeding female;

          -  Aged ≥ 18 years;

          -  Patient with:

               -  advanced HCC (BCLC-C according to BCLC staging classification) having progressed
                  under sorafenib therapy or intolerant to sorafenib, or;

               -  intermediate HCC (BCLC-B) non eligible or non responders to transarterial
                  chemoembolization (TACE), and having progressed under or intolerant to sorafenib
                  therapy

          -  HCC diagnosed according to the AASLD criteria:

               -  Cyto-histology criteria and/or Non-invasive criteria

          -  Without cirrhosis or with a non decompensated cirrhosis (Child-Pugh score from A5 to
             B7 included);

          -  ECOG Performance Status 0 or 1;

          -  Laboratory tests as follows:

               -  Platelets ≥ 50,000 /mm3

               -  Neutrophil count ≥ 1000/mm3

               -  Hemoglobin ≥ 10g/dL

               -  Serum transaminases &lt; 5 ULN (NCI/CTC grades 0, 1, or 2)

               -  Alkaline phosphatases &lt; 5 ULN (NCI/CTC grades 0, 1, or 2)

               -  Serum bilirubin &lt; 35 µM/L (or 2.0 mg/dL);

          -  Signed and dated written informed consent form.

        Exclusion Criteria:

          -  Cirrhosis with a Child-Pugh score B8-C15;

          -  Untreated chronic hepatitis B;

          -  Patients eligible for curative treatments (transplantation, surgical resection,
             percutaneous treatment);

          -  Patients eligible for palliative treatments with demonstrated efficacy: TACE,
             sorafenib (patients who failed to sorafenib treatment or intolerant to sorafenib can
             be included);

          -  HCC developed on transplanted liver;

          -  HIV infection;

          -  Risk of variceal bleeding;

          -  SaO2 &lt; 95%;

          -  Presence of a significant acute or chronic respiratory disease, pleural effusion;

          -  Presence of recent (&lt; 6 months) or current cardiac failure (class III or IV NYHA
             classification), recent (&lt; 6 months) acute coronary syndrome, clinically significant
             ECG abnormalities or recent (less than 6 months) acute vascular diseases (stroke,
             MI…);

          -  Patients having undergone a 450 mg/m² cumulated dose of doxorubicin;

          -  Patients currently treated with immunosuppressive agents that cannot be stopped;

          -  Patients with unstable ongoing medical/surgical problems;

          -  Patients with a life expectancy of less than 2 months;

          -  Patients who had participated in another clinical trial in the last 30 days;

          -  Women of child-bearing age who are unwilling or unable to use an effective
             contraception method during the study treatment period and for 2 months after the
             last administration of study drug, and  their male partner(s) refusing to use a
             condom (if applicable);

          -  Men who are unwilling or unable to use a condom during the study treatment period and
             for 2 months after the last administration of study drug, and their female partner(s)
             refusing to use one of the appropriate effective contraception methods (if
             applicable);

          -  Patients unwilling or unable to comply with protocol requirements and scheduled
             visits.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Merle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Croix-Rousse Hospital - Lyon-France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Berangere Vasseur, MD</last_name>
    <phone>+33 (0)1 45 58 76 04</phone>
    <email>berangere.vasseur@bioalliancepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Nguyen-Khac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul CALES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Di Martino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Frédérique Blanc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Isabelle OLLIVIER-HOURMAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Armand Abergel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Henri-Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Charlotte Costentin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Inter-Communal</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Isabelle ROSA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick HILLON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrick HILLON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Pierre Zarski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nicole TUBIANA-MATHIEU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Merle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Santandrea Gerolami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georges-Philippe Pageaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Pierre Bronowicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yann Touchefeu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Albert TRAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barbara Dauvois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pitié-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vlad Ratziu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Didier Grange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olivier ROSMORDUC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Julien TAIEB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Faiza Khemissa-Akouz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Driffa Moussata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IC LOIRE</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc PHELIP, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Marc PHELIP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Doffoel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles Pelletier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 3, 2013</lastchanged_date>
  <firstreceived_date>July 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intermediate/advanced hepatocellular carcinoma</keyword>
  <keyword>After failure or intolerance to Sorafenib.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
